• Explore /
  • Poster
  • / Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).

Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).

Abstract Poster

Authors

Marc Uemura

Marc Isamu Uemura

The University of Texas MD Anderson Cancer Center, Houston, TX

Marc Isamu Uemura, Cara L. Haymaker, Ravi Murthy, Marihella James, Mark Cornfeld, Srinivas Chunduru, Sudhir Agrawal, Cassian Yee, Jennifer A. Wargo, Rodabe Navroze Amaria, Sapna Pradyuman Patel, Hussein Abdul-Hassan Tawbi, Isabella Claudia Glitza, Scott Eric Woodman, Wen-Jen Hwu, Michael A. Davies, Patrick Hwu, Willem W Overwijk, Chantale Bernatchez, Adi Diab

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells

Sub Track

Toll-Like Receptors (TLRs)

Clinical Trial Registration Number

NCT02644967

Citation

J Clin Oncol 35, 2017 (suppl 7S; abstract 136)

DOI

10.1200/JCO.2017.35.7_suppl.136

Abstract #

136

Poster Bd #

K10

Abstract Disclosures

Similar Posters

First Author: Adi Diab

First Author: Mohammed M. Milhem

First Author: Alberto Fusi

First Author: Vincent The-Luc Ma